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Abstract
OBJECTIVE—We examined screening practices and attitudes of obstetricians-gynecologists 
toward the use of noncombustible tobacco products (chewing tobacco, snuff/snus, electronic 
cigarettes, and dissolvables) during pregnancy.
STUDY DESIGN—The authors mailed a survey in 2012 to 1024 members of the American 
College of Obstetricians and Gynecologists, including Collaborative Ambulatory Research 
Network (CARN) and non-CARN members. Stratified random selection was used to generate 
CARN and non-CARN samples.
RESULTS—Response rates were 52% and 31% for CARN and non-CARN members, 
respectively. Of 252 total eligible respondents (those currently providing obstetrics care) 53% 
reported screening pregnant women at intake for noncombustible tobacco product use all or some 
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of the time, and 40% reported none of the time. Respondents who reported that noncombustible 
products have adverse health effects during pregnancy, but are safer than cigarettes, ranged from 
20.2% (dissolvables) to 29% (electronic cigarettes) and that the health effects are the same as 
those of cigarettes from 13.5% (electronic cigarettes) to 53.6% (chewing tobacco). Approximately 
14% reported that electronic cigarettes have no adverse health effects; <1% reported no health 
effects for the remaining products. Two-thirds of the respondents wanted to know more about the 
potential health effects of noncombustible tobacco products; only 5% believed themselves to be 
fully informed.
CONCLUSION—A large proportion of obstetrician-gynecologists reported never or 
inconsistently screening their pregnant patients for the use of noncombustible tobacco products. 
Responses regarding the harms of these products relative to cigarettes were mixed and most 
respondents wanted more information. Development and dissemination of guidance for providers 
is needed to improve decision-making regarding noncombustible tobacco products.
Keywords
electronic cigarette; obstetrician-gynecologist; pregnancy; smokeless tobacco
Maternal smoking is one of the most prevalent modifiable risk factors for poor birth 
outcomes. The American College of Obstetrics and Gynecologists recommends that 
smoking cessation strategies should be integrated into routine prenatal care for every 
pregnant woman.1 Maternal smoking causes ectopic pregnancy, fetal growth restriction, 
preterm delivery, placenta previa, placental abruption, and sudden infant death syndrome.2,3 
The roles of individual tobacco components underlying these relationships, such as nicotine, 
are not understood fully.
For more than a decade, the public health community has debated whether access to 
smokeless tobacco products such as chewing tobacco and snus (moist snuff packaged in 
pouches that resemble small tea bags) could reduce tobacco-related morbidity and death.4 
Unlike cigarette smoking, smokeless tobacco does not expose the user to products of 
combustion. This means smokeless products are inherently less hazardous overall than 
cigarettes, although not without risk.5 Recently, the introduction of novel, noncombustible 
products has added momentum to the debate because of their purported low toxicity.6,7 
These products include dissolvable tobacco (finely milled tobacco pressed into tablets, 
strips, or sticks) that slowly dissolves in the user’s mouth8,9 and electronic cigarettes or 
electronic cigarettes (electronic nicotine delivery systems that utilize a heating element that 
aerosolizes a liquid solution such as propylene glycol frequently combined with nicotine and 
flavorings).10 The implications of the increasing availability of smokeless tobacco and other 
noncombustible tobacco products for pregnant women are unclear.
The US Food and Drug Administration (FDA) has the authority to allow companies to 
market products with a claim to reduce risk of tobacco-related disease (modified-risk 
tobacco products) if the company can demonstrate that the product, as used by consumers, 
will reduce significantly the risk of tobacco-related disease to individuals as well as benefit 
the health of the population as a whole. 11 To date, no applications for noncombustible 
tobacco products have been approved by the FDA for harm reduction claims. However, 
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messages that imply product safety frequently appear in the media, through direct 
advertising, product placement in television and movies, and the internet by personal 
testimonials, especially for electronic cigarettes.12-15
Research on the health effects of noncombustible tobacco product use during pregnancy is 
limited; however, adverse outcomes, which include preterm delivery, stillbirth, and infant 
apnea, have been reported for smokeless tobacco.16-21 Data regarding the effects of nicotine 
on the developing fetus are sufficient to have resulted in the classification of nicotine as a 
reproductive toxicant by the California Environmental Protection Agency.22 Subsequently, 
the 2014 Surgeon General’s Report on the Health Consequences of Smoking concluded that 
the evidence is sufficient to infer that nicotine exposure during fetal development has lasting 
adverse consequences for brain development and contributes to adverse pregnancy 
outcomes.3 Therefore, the effects of nicotine on fetal health from maternal use of 
noncombustible tobacco products are of great concern.
Behavioral counseling is an effective strategy for smoking cessation during pregnancy,23 
and the 2011 College Committee Opinion on tobacco use includes instructions in the “Ask” 
portion of the 5 As (Ask, Assess, Advise, Assist, and Arrange) that the provider should 
inquire about tobacco use in any form in the past year, which includes cigarettes, cigars, 
smokeless tobacco, hookah, or electronic cigarettes.1 In this study, we explored screening 
practices and attitudes of obstetricians-gynecologists toward smokeless tobacco products 
(chewing tobacco, snuff/snus, dissolvable tobacco products, and electronic cigarettes). 
Because it has been suggested that noncombustible products may be beneficial as a way to 
cut down the number of cigarettes smoked,24,25 we also assessed whether physicians 
believed that reducing the number of cigarettes smoked per day has health benefits for 
pregnant women who do not quit completely.
Materials and Methods
Study population and survey administration
Data were collected by the College Research Department of the American College of 
Obstetricians and Gynecologists with a self-administered survey mailed in February 2012 to 
1024 American College of Obstetricians and Gynecologists Fellows, 425 of whom were 
members of the College Collaborative Ambulatory Research Network (CARN) and 599 
were non-CARN members. CARN members are practicing College Fellows or Junior 
Fellows who have volunteered to participate in the College Research Department surveys 
and are sent four-to-five surveys per year. The non-CARN group was comprised of 
practicing obstetricians-gynecologists who are College Fellows but not CARN members. 
Stratified random selection was used for both samples. The total memberships for each 
group were divided into groups of approximately 100 individuals that were similar in age, 
sex, and geographic distribution; the samples were then randomly selected from each 
membership list.
The College Research Department maintains membership on an ongoing basis to inform and 
evaluate the College’s efforts to provide guidance on clinical practice to its Fellows.26 All 
potential participants received in the mail an introductory cover letter, the questionnaire, and 
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a postage-paid return envelope. Those who did not respond were sent up to 3 reminder 
mailings through June 2012. Eligible participants were those who returned completed 
questionnaires and who confirmed that they were currently providing obstetrics care.
The cover letter outlined the purpose of the study and informed participants that their 
responses were anonymous and confidential. Response to the survey served as informed 
consent. This project was deemed exempt from review by the Institutional Review Board at 
American College of Obstetricians and Gynecologists.
Survey questions that were relevant to the current analysis assessed screening practices and 
attitudes toward the use of noncombustible tobacco products during pregnancy and toward 
reduction of the number of cigarettes smoked by women who do not quit completely (Table 
1). Other survey questions that were used in this analysis included year of completion of 
obstetrics/gynecology residency, type of primary employment site, estimated percentage of 
patients enrolled in Medicaid, sex, practice type (obstetrics only, gynecology only, or both), 
provision of comprehensive primary care, ethnicity, race, employment setting (urban or 
rural), and personal smoking history. Other questions not used in this analysis addressed 
smoking cessation counseling practices and barriers to the provision of counseling.
Analysis
We calculated frequencies of responses to survey questions and included nonresponses in 
the denominator for each question. We quantified nonresponses to provide additional insight 
into clinicians’ knowledge. χ2 tests were used to assess relationships between selected 
clinician characteristics (sex, provision of comprehensive primary care, and years since 
completing residency) and whether respondents screened their pregnant patients at intake for 
noncombustible tobacco product use. A 2-tailed probability of < .05 was considered 
statistically significant. Data were analyzed with SAS software (version 9.2; SAS Institute 
Inc, Cary, NC).
Results
One thousand twenty-four surveys were mailed; 405 members (40%) returned completed 
surveys, of whom 221 respondents were CARN members (52% response rate) and 184 
respondents were non-CARN members (31% response rate). Two hundred fifty-two 
respondents practiced obstetrics and were included in the final analysis; 157 respondents 
were CARN members, and 95 respondents were non-CARN members. CARN and non-
CARN respondents in the final analysis did not differ by sex, race, practice location, practice 
type, or percentage of patients enrolled in Medicaid.
Respondents’ characteristics are summarized in Table 2. Briefly, 81.7% were white; 55.6% 
were female; 78.2% had never smoked; 15.5% were former smokers, and 2.4% were active 
smokers (the remainder did not answer the question); 46% practiced in a group practice/
health maintenance organization; 78.6% practiced in an urban/suburban area, and 30.6% 
provided comprehensive primary care. The mean number of years since completion of 
residency was 19.4.
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Attitudes toward smoking cessation and reduction
Nearly all respondents (94%) reported that they believed it was very important or important 
for their patients to stop smoking. Approximately one-third of the respondents (31%) 
reported that they believed it was likely or very likely that they/their practice could help 
pregnant patients to quit smoking; approximately one-half of them (49.6%) reported that 
they believed it was somewhat likely, and 12.7% of them reported that it was unlikely. 
These findings did not vary by the sex of the respondent, whether the respondent provided 
comprehensive primary care, or by years since residency was completed (>30, 20-30, or 
10-19 or <10 years; P >.05). Eighty-six percent of respondents said that they believed it was 
very important for their patients who did not quit smoking to at least cut down of the number 
of cigarettes smoked; only 4% said it was somewhat important to cut down. Zero 
respondents said it was not important.
Screening practices and attitudes toward noncombustible tobacco products
Forty percent of respondents reported that they never ask patients at intake about their 
noncombustible tobacco use; 29.0% of the respondents reported that they ask sometimes, 
and 24.2% of them reported that they always ask; 6.8% of the respondents did not answer 
the question. These findings did not vary by sex, percentage of pregnant patients covered by 
Medicaid (<25% vs ≥25%), employment setting (urban/suburban vs rural), whether the 
respondent provided comprehensive primary care, or by years since residency was 
completed (P > .05). The percentage of respondents who reported that noncombustible 
products have adverse health effects but are safer than cigarettes ranged from 20.2% 
(dissolvable tobacco products) to 29% (electronic cigarettes). The percentage who reported 
the health effects are the same as those of cigarettes ranged from 13.5% (electronic 
cigarettes) to 53.6% (chewing tobacco). Zero percent reported that chewing tobacco, snuff/
snus, or dissolvable products have no health effects; 13.5% reported that electronic 
cigarettes have no health effects. A high percentage of respondents answered “don’t know” 
or did not respond to questions about relative safety (19.5-44.4%; Table 3).
Two-thirds of respondents (67.5%) reported wanting to know more about the potential 
health effects of noncigarette tobacco products. Eighteen percent did not want more 
information because (1) their patients were not using these products (11.9%), (2) they did 
not believe these products affected their patients’ health (0.8%), or (3) they already believed 
that they were informed fully about the health risks (5.2%). The remaining reported that they 
did not know whether they wanted more information (9.5%) or did not answer the question 
(5.2%). The percentage of respondents who indicated that they wanted more information 
about the health effects of noncombustible products did not vary by reported screening 
practices for noncombustible product use.
Comment
The tobacco product landscape is changing rapidly and now includes many new, 
noncombustible products. Although the prevalence of smokeless tobacco product use in US 
women is currently low,27 tobacco companies actively are marketing noncombustible 
products, such as Camel Snus, to women.28-30 Numerous electronic cigarette advertisements 
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feature young or even pregnant women, and electronic cigarettes are becoming increasingly 
popular among both men and women.31,32 Pregnant smokers who seek to reduce harm to 
their babies or to avoid that stigma associated with smoking could be especially vulnerable 
to the allure of noncombustible products.
Smokeless tobacco does not expose the user to products of combustion, such as carbon 
monoxide. Carbon monoxide is a known fetal teratogen and is believed to contribute to 
adverse pregnancy outcomes such as fetal growth restriction.33 However, all smokeless 
tobacco products and most electronic cigarette products contain nicotine, which has been 
associated with a number of adverse effects on reproductive health. These effects include 
impaired oviduct function, decreased fetal and infant lung weight, volume, and function3,34; 
effects on fetal brain development include cell damage, reduced cell number, impaired 
synaptic activity, premature change from cell replication to differentiation, and the initiation 
of apoptosis.3,35-37 Reports of associations between smokeless tobacco and adverse 
outcomes suggest that exposure to nicotine-containing products during pregnancy could 
have substantial health consequences, even in the absence of combustion.16-21 In Sweden, 
for example, snus use and smoking during pregnancy were both associated with increased 
risks of preterm birth, and the magnitude of the associations were similar (adjusted odds 
ratios, 1.29 and 1.30, respectively).16 In a separate analysis, the risk of stillbirth was 
significantly increased in snus users compared with tobacco nonusers (adjusted odds ratio, 
1.6); the risk was higher for preterm stillbirth (adjusted odds ratio, 2.1).20 No epidemiologic 
studies to date have assessed the effects of smokeless tobacco use on offspring 
neurodevelopment or risk of sudden infant death syndrome.
There have been no studies that have examined pregnancy outcomes associated with 
dissolvable tobacco products or electronic cigarettes. A 2012 report to the FDA by the 
Tobacco Products Scientific Advisory Committee concluded that exclusive use of 
dissolvable tobacco products by an individual would reduce greatly the risk for smoking-
caused disease compared with regular use of cigarettes,38 but the report did not address 
health risks in pregnant women.
Electronic cigarettes currently are unregulated and are available widely in the United States. 
Recent product modifications include large, refillable cartridges to hold more nicotine 
solution (also called “tank” systems). Products vary widely in their nicotine concentration, 
in their actual nicotine delivery, and in quality control.39 There have been no studies 
published that assess pregnancy outcomes in electronic cigarette users. However, calls to 
poison control centers in the United States regarding exposure to electronic cigarette 
products/components in children and young adults have sky-rocketed in recent years and 
now account for >40% of combined electronic cigarette and cigarette exposure calls.40
Although switching from conventional cigarettes to noncombustible products may reduce 
exposure to many toxins, it is unclear whether pregnant women who choose to use 
noncombustible products will stop smoking cigarettes entirely in favor of these new 
products or will use these products in combination with cigarettes. There is a paucity of data 
on whether smokeless tobacco and electronic cigarettes are effective smoking cessation 
aids,41 and adult electronic cigarette use appears to be highest among active smokers.42 The 
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potential for dual use of cigarettes and noncombustible products remains a major concern for 
the general population and for pregnant women.
Previous studies have demonstrated that a very high percentage of obstetricians screen 
pregnant women for tobacco use.43,44 In our study, nearly all respondents reported that it 
was very important or important for their patients to stop smoking, and over threefourths of 
the respondents reported that they believed it was somewhat likely, likely, or very likely that 
they/their practice could help pregnant patients to quit. This supports previous studies that 
found that obstetricians-gynecologists view smoking cessation as a priority for them and/or 
their practice.43,44 Although >50% of providers reported screening pregnant women at 
intake for noncombustible tobacco product use at least some of the time, 40% reported that 
they never ask. This could reflect a lack of awareness of the availability and/or the adverse 
health effects of these products. For example, the recent College Committee Opinion on 
Tobacco Use does not address directly cessation interventions for smokeless tobacco use or 
the relative harms of noncombustible and combustible tobacco products.1
Our finding that 42% of respondents believed that electronic cigarettes are safer than 
conventional cigarettes or have no health effects was in contrast to beliefs about other 
noncombustible products that were often reported to be as hazardous as cigarettes. This 
finding could be the result of publicity regarding electronic cigarettes as a safe alternative to 
smoking on television, in movies, and on the internet.11,13 In contrast, most noncombustible 
tobacco products (chewing tobacco, snuff, and snus) are regulated by the FDA and must 
carry package warning labels; companies are prohibited from making or implying reduced 
harm claims.45,46 Media messages implying reduced harm from electronic cigarettes may be 
reaching providers as well as the general public.
Most respondents in the current study reported that they would like to know more about the 
potential health effects of noncombustible tobacco products; only 5% of respondents 
reported that they already believed themselves to be fully informed. Although nicotine is a 
known reproductive toxicant,3,22 13.5% of respondents reported that electronic cigarettes 
have no health effects. In addition, a high percentage of respondents either reported that they 
did not know what the health effects of the noncombustible products were (13-40%) or did 
not answer the question (6-7%). These finding could reflect the increasing visibility of these 
products and a concurrent paucity of educational messages that target providers.
Most respondents (85%) in our study reported that it was “very important” for their patients 
who did not quit to cut down on the number of cigarettes smoked. However, there is little 
evidence to support that reducing the number of cigarettes smoked per day without quitting 
results in substantial improvements in health47,48 or pregnancy outcomes.48 Although data 
support that reducing the number of cigarettes smoked without cessation can result in 
improvements in birthweight,49,50 little is known about other outcomes. Although it is 
unlikely that reducing the number of cigarettes increases harm (unless compensatory 
smoking actually increased the exposure to toxicants), it is possible that improvements in 
outcomes are less than clinicians and patients might anticipate. Therefore, the benefits of 
reducing the number of cigarettes smoked without quitting should not be overstated to 
pregnant women, particularly if it undermines cessation efforts. In addition, some data 
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suggest that women must reduce to a low level of exposure to cigarettes before substantial 
benefits in birthweight are observed.51 There are currently no recommendations from the 
College as to whether and how much women should cut back to experience improved 
outcomes.
This study has several limitations; the sample size is small, and the results were not 
validated by a review of medical records or other clinical data. We cannot confirm that 
reported practice reffects actual practice, and the response rates to this survey (31-52%) are 
not sufficient to exclude the possibility of nonresponse bias. Therefore, our results may not 
be generalizable to the overall College membership. However, the response rate is consistent 
with those of previous College surveys, and studies have shown that nonresponse bias tends 
to be less problematic among physicians than among other groups.52 Selection bias because 
of the use of the CARN for part of the sample is not likely to be problematic, because there 
were few differences in demographic characteristics or responses to questions (similar to 
previous studies).53-55
In conclusion, a large proportion of obstetrician-gynecologists reported never or 
inconsistently screening their pregnant patients for the use of noncombustible tobacco 
products, and most respondents reported a desire to know more about the health effects of 
these products. The risks of the use of noncombustible products during pregnancy have not 
been quantified fully, and existing information about the relative harms of noncombustible 
tobacco products for the general population should not be generalized to pregnant women. 
Currently, there are limited data to support the use of noncombustible tobacco products as 
cessation aids, and evidence suggests that the use of noncombustible products such as snus 
during pregnancy can result in adverse pregnancy outcomes. Development and 
dissemination of guidance for providers could improve decision-making regarding 
noncombustible tobacco products.
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TABLE 1
Questionnaire items from the survey of American College of Obstetricians and Gynecologists members, 2012 
(n = 241)
Theme Questions and answer options
Smoking cessation How important do you personally believe that it is for
women who smoke to stop smoking during pregnancy?
Very important, Important, Somewhat important, Not very
important, Not at all important.
In your opinion, how likely is it that you/your practice can
help your pregnant patients to stop smoking? Very likely,
Likely, Somewhat likely, Unlikely, Don’t know.
Reduction of cigarette use In your opinion, how important is it to your patients’ health
during pregnancy that your patients who can’t stop
smoking at least cut down on the number of cigarettes




Do you ask you pregnant patients at intake if they use
noncigarette tobacco products such as chewing tobacco,
snuff, snus, electronic cigarettes, or dissolvable tobacco
products? Always, Sometimes, Never.
How would you rate the health effects of the following
tobacco products in pregnant women? For each product
(chewing tobacco/snuff/snus, electronic cigarettes,
dissolvable tobacco products): No health effects, Adverse
effects but safer than cigarettes, Adverse effects the same
as cigarettes, I don’t know.
Would you like to know more about potential health effects
of noncigarette tobacco products such as chewing
tobacco, snuff, snus, electronic cigarettes, or dissolvable
tobacco products? No, because no one in my practice uses
these products; No, because I don’t believe these products
would affect my patients’ health; No, because I already
believe that I am fully informed; Yes; Not sure.
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TABLE 2
Characteristics of obstetrician-gynecologist physician participants
Physician characteristics Measure
Years since residency completed
a 19.4 ± 9.3
Sex female, % 55.6
Racial group white, % 81.7
Hispanic ethnicity, % 3.2
Provides comprehensive primary care, % 30.6






 Never smoked regularly 78.2
 Former smoker 15.5
 Current smoker, trying to quit 0.8
 Current smoker, not trying to quit 1.6
 Missing 3.9
Practice type, %
 Solo practice/2-clinician practice 21.0
 Hospital or clinic 15.9
 Group practice/staff model health maintenance
 organization 46.0
 Community health center 3.6
 Medical school/university 8.7
 Other 2.0
From the survey of American College of Obstetricians and Gynecologists members, 2012 (n = 252 respondents).
a
Data are given as mean ± SD.
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TABLE 3
Clinician assessment of health effects of noncigarette products








cigarettes Don’t know Missing
Chewing
tobacco
1 (0.4) 67 (26.6) 135 (53.6) 33 (13.1) 16 (6.4)
Snuff/snus 0 60 (23.8) 125 (49.6) 50 (19.8) 17 (6.8)
Electronic
cigarettes
34 (13.5) 73 (29.0) 34 (13.5) 92 (36.5) 19 (7.5)
Dissolvable
tobacco
0 51 (20.2) 89 (35.5) 93 (36.9) 19 (7.5)
From the survey of American College of Obstetricians and Gynecologists members, 2012 (n = 252 respondents).
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